InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,660.00
(
0.33%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.13
(
0.21%
)
Bitcoin
62,765.83
(
-0.45%
)
Post# of 251777
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JohnWayne

Send PM Follow Ignore
Followers 6
Posts 271
Boards Moderated 0
Alias Born 12/22/2011

JohnWayne

Re: jq1234 post# 212161

Wednesday, 06/28/2017 2:57:50 PM

Wednesday, June 28, 2017 2:57:50 PM

Post# of 251777
Agreed. There's a place for more tolerable TKIs in combination with PD1/PD-L1, but that ship has probably sailed for tivo given the axitinib studies. When 1L market changes to PD1 combos, I wouldn't be surprised to see EXEL get a huge bump in its 2L business since there's no data to support re-treatment with nivolumab
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up